DAWNZERA Trademark

Trademark Overview


On Monday, June 5, 2023, a trademark application was filed for DAWNZERA with the United States Patent and Trademark Office. The USPTO has given the DAWNZERA trademark a serial number of 98027554. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Wednesday, September 25, 2024. This trademark is owned by Ionis Pharmaceuticals, Inc.. The DAWNZERA trademark is filed in the Education & Entertainment Services category with the following description:

Education and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; online journals, namely, blogs featuring information on autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders
dawnzera

General Information


Serial Number98027554
Word MarkDAWNZERA
Filing DateMonday, June 5, 2023
Status731 - SECOND EXTENSION - GRANTED
Status DateWednesday, September 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 22, 2023

Trademark Statements


Goods and ServicesEducation and training services, namely, seminars, providing non-downloadable webinars, and workshops for healthcare professionals, caregivers, patients, and providers in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; online journals, namely, blogs featuring information on autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders

Classification Information


International Class041 - Education; providing of training; entertainment; sporting and cultural activities.
US Class Codes100, 101, 107
Class Status Code6 - Active
Class Status DateSunday, July 9, 2023
Primary Code041
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIonis Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCarlsbad, CA 92010

Party NameIonis Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCarlsbad, CA 92010

Trademark Events


Event DateEvent Description
Thursday, June 8, 2023NEW APPLICATION ENTERED
Sunday, July 9, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, July 18, 2023ASSIGNED TO EXAMINER
Tuesday, July 18, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 17, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 2, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 22, 2023PUBLISHED FOR OPPOSITION
Tuesday, August 22, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 12, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, March 12, 2024SOU EXTENSION 1 GRANTED
Tuesday, March 12, 2024SOU EXTENSION 1 FILED
Wednesday, March 13, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 25, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, September 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 25, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, September 25, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 25, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, September 25, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, September 25, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, September 25, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, September 25, 2024SOU EXTENSION 2 GRANTED
Wednesday, September 25, 2024SOU EXTENSION 2 FILED